STOCK TITAN

DXCM Form 144: Sadie Stern Plans Sale via Morgan Stanley; Recent June/July Sales Reported

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

DexCom Form 144 summary: This notice reports proposed sales of 1,466 shares of DexCom common stock to be executed through Morgan Stanley Smith Barney LLC on 09/04/2025 on NASDAQ, with an aggregate market value listed at $117,280.00. The filings show the same filer, Sadie Stern, sold 1,466 shares on 07/28/2025 for $130,459.34 and 1,466 shares on 06/26/2025 for $124,697.96 during the past three months. The securities to be sold were originally acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares). The filer affirms no undisclosed material adverse information.

Positive

  • Required Rule 144 details provided including broker, share counts, acquisition dates, and recent sales
  • Origin of shares disclosed as restricted stock acquired from the issuer on specific dates

Negative

  • Insider sales reported (1,466 shares planned; 1,466 shares sold 07/28/2025; 1,466 shares sold 06/26/2025)
  • Aggregate market value noted for the planned sale is $117,280.00, indicating insider liquidity activity

Insights

TL;DR: Routine insider sale notice showing limited share blocks sold via a broker; not a material financing or corporate change.

The Form 144 documents proposed and recent sales by an individual identified as Sadie Stern. The notice lists a planned sale of 1,466 shares with an aggregate market value of $117,280 executed through Morgan Stanley Smith Barney on NASDAQ. Two prior sales in June and July 2025 are reported with gross proceeds disclosed. Acquisition dates and that the shares originated as restricted stock are provided, which supports that these are controlled dispositions of previously granted equity rather than open-market issuances. Impact appears informational rather than company-altering.

TL;DR: Disclosure follows Rule 144 mechanics; shows compliance with sale aggregation and broker execution requirements.

The filing supplies the required details under Rule 144: broker name, share counts, acquisition method, and recent related sales. The signer represents absence of undisclosed material adverse facts and notes plan/trading-instruction fields are present though not populated. From a governance perspective, the form documents insider liquidity actions and demonstrates procedural compliance; it does not disclose changes in management, control, or corporate policy.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does DexCom's (DXCM) Form 144 filed here disclose?

The filing discloses a proposed sale of 1,466 shares via Morgan Stanley Smith Barney on NASDAQ (09/04/2025) with aggregate market value $117,280.00 and two prior sales in June and July 2025.

Who is the seller named in this Form 144 for DXCM?

The seller identified in the document is Sadie Stern, with recent sales and the proposed sale described in the filing.

How were the shares being sold originally acquired?

The securities were acquired as restricted stock from the issuer on 12/15/2023 (978 shares) and 11/19/2023 (488 shares).

What broker is handling the proposed sale in this Form 144?

The broker named for the proposed sale is Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.

What proceeds were realized from recent insider sales reported in the filing?

Proceeds listed: $130,459.34 for the 07/28/2025 sale and $124,697.96 for the 06/26/2025 sale
Dexcom Inc

NASDAQ:DXCM

DXCM Rankings

DXCM Latest News

DXCM Latest SEC Filings

DXCM Stock Data

27.18B
388.32M
0.42%
97.51%
2.83%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO